XML 42 R30.htm IDEA: XBRL DOCUMENT
v3.22.1

License and Collaboration Agreement - Narrative (Details) - USD ($) |  | 3 Months Ended | 12 Months Ended |  |  |
--- | --- | --- | --- | --- | --- | ---
Jul. 27, 2021 | Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021 | Mar. 31, 2020 | May 07, 2019 | Jul. 13, 2017
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Recognized revenue from deferred revenue contract liability |  | $ 13,000 | $ 1,100,000 |  |  |  |
Janssen | Services performed for IL-23 receptor antagonist compound research costs and other services |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Reimbursement for services performed |  | 17,900,000 |  |  |  |  |
Janssen | License and Collaboration Agreement |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Collaboration revenue recorded following the contract modification |  | 25,700,000 | 5,600,000 |  |  |  |
Janssen | License and Collaboration Agreement | Three phase 1 studies of second-generation compounds |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Eligible amount received |  |  |  | $ 7,500,000 |  |  |
Janssen | License and Collaboration Agreement | 3rd patient in the first Phase 2 clinical trial for any second-generation compound for a second indication |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Eligible amount received |  | 25,000,000.0 |  |  |  |  |
Janssen | License and Collaboration Agreement | Phase 3 clinical trial for a second-generation compound for any indication |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Upcoming potential development milestones |  | 115,000,000.0 |  |  |  |  |
Janssen | License and Collaboration Agreement | Completion of clinical data collection for Phase 1 activities for the first of either PN-232 or PN-235 |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Upcoming potential development milestones |  | 25,000,000.0 |  |  |  |  |
Janssen | Original Agreement |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Transaction price |  |  |  | 106,500,000 |  |  |
Janssen | Original Agreement | License and Collaboration Agreement |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Duration of the parties' research collaboration agreement | 2 years |  |  |  |  |  |
Janssen | Original Agreement | License and Collaboration Agreement | Three phase 1 studies of second-generation compounds |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Expense obligations eliminated | $ 5,000,000.0 |  |  |  |  |  |
Percentage of development cost eliminated | 50.00% |  |  |  |  |  |
Janssen | Original Agreement | License and Collaboration Agreement | Phase 2a and 2b costs for PTG-200 |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Development cost payable |  | $ 100,000,000.0 |  |  |  |  |
Development cost incurred, percentage |  | 20.00% |  |  |  |  |
Janssen | Original Agreement | License and Collaboration Agreement | Phase 2 studies for second-generation products |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Percentage of development cost eliminated | 20.00% |  |  |  |  |  |
Milestone payment |  |  |  |  |  |  | $ 50,000,000.0
Janssen | Original Agreement | License and Collaboration Agreement | Maximum | Three phase 1 studies of second-generation compounds |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Development cost payable |  |  |  |  |  |  | 20,000,000.0
Janssen | Original Agreement | License and Collaboration Agreement | Maximum | Phase 2a and 2b costs for PTG-200 |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Development cost payable |  |  |  |  |  |  | 20,000,000.0
Janssen | Original Agreement | License and Collaboration Agreement | Maximum | Phase 2 studies for second-generation products |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Development cost payable |  | $ 25,000,000.0 |  |  |  |  |
Expense obligations eliminated | $ 25,000,000.0 |  |  |  |  |  |
Janssen | Original Agreement | Upfront cash payment |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Upfront payment |  |  |  |  |  |  | $ 50,000,000.0
Janssen | Restated Agreement |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Upfront payment |  | 87,500,000 |  |  |  |  |
Development cost payable |  | 7,100,000 |  |  |  |  |
Reimbursement for services performed |  | 8,200,000 |  |  |  |  |
Maximum percentages royalties on net product sales | 10.00% |  |  |  |  |  |
Increase (decrease) in transaction price |  | 25,000,000.0 |  | $ 8,000,000.0 |  |  |
Transaction price |  | $ 131,500,000 |  |  |  |  |
Janssen | Restated Agreement | Second-generation Oral Interleukin ("IL")-23 Receptor Antagonist Development Compound |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Eligible amount received |  |  |  |  | $ 5,000,000.0 |  |
Janssen | Restated Agreement | Phase 2a study evaluating PTG-200 for the treatment of CD |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Development cost incurred, percentage |  | 50.00% |  |  |  |  |
Janssen | Restated Agreement | Additional services |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Revenue recognized |  | $ 0 | $ 600,000 |  |  |  |
Janssen | Restated Agreement | License and Collaboration Agreement |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Eligible amount received |  |  |  |  |  | $ 25,000,000.0 |
Janssen | Restated Agreement | License and Collaboration Agreement | Phase 1 studies of second-generation compounds |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Percentage of development cost eliminated |  | 100.00% |  |  |  |  |
Janssen | Restated Agreement | License and Collaboration Agreement | Phase 2 studies for second-generation products |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Upcoming potential development milestones |  | $ 25,000,000.0 |  |  |  |  |
Milestone payment | $ 25,000,000.0 |  |  |  |  |  |
Janssen | Restated Agreement | License and Collaboration Agreement | 3rd patient in the first Phase 2 clinical trial for any second-generation compound for a second indication |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Upcoming potential development milestones |  | $ 10,000,000.0 |  |  |  |  |
Janssen | Restated Agreement | License and Collaboration Agreement | Phase 2a study evaluating PTG-200 for the treatment of CD |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Development cost incurred, percentage |  | 20.00% |  |  |  |  |
Janssen | Restated Agreement | License and Collaboration Agreement | Dosing of the 3rd patient in a Phase 3 clinical trial for a second-generation compound for any indication |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Upcoming potential development milestones |  | $ 50,000,000.0 |  |  |  |  |
Janssen | Restated Agreement | License and Collaboration Agreement | Dosing Of Third Patient In Phase 3 Clinical Trial For Second Generation Compound For A Second Indication [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Upcoming potential development milestones |  | 15,000,000.0 |  |  |  |  |
Janssen | Restated Agreement | License and Collaboration Agreement | Maximum | Phase 2a study evaluating PTG-200 for the treatment of CD |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Development cost payable |  | $ 20,000,000.0 |  |  |  |  |

X
- Definition The amount of upfront payment based on the agreement. + References No definition available. + Details
Name: | ptgx_CollaborativeAgreementUpfrontPayment
Namespace Prefix: | ptgx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the amount received from a collaborative arrangement. + References No definition available. + Details
Name: | ptgx_CollaborativeArrangementEligibleAmountReceived
Namespace Prefix: | ptgx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the percentage of development cost incurred. + References No definition available. + Details
Name: | ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred
Namespace Prefix: | ptgx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the percentage of development cost eliminated. + References No definition available. + Details
Name: | ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurredEliminated
Namespace Prefix: | ptgx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the development costs that have been eliminated. + References No definition available. + Details
Name: | ptgx_DevelopmentCostsEliminated
Namespace Prefix: | ptgx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the duration of the parties' research collaboration agreement. + References No definition available. + Details
Name: | ptgx_DurationOfResearchCollaborationAgreement
Namespace Prefix: | ptgx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentages on net product sales. + References No definition available. + Details
Name: | ptgx_PercentagesRoyaltiesOnNetProductSales
Namespace Prefix: | ptgx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the amount of reimbursement for services performed. + References No definition available. + Details
Name: | ptgx_ReimbursementForServicesPerformed
Namespace Prefix: | ptgx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of development cost payable under the collaboration agreement. + References No definition available. + Details
Name: | ptgx_ResearchAndCollaborationAgreementDevelopmentCostPayable
Namespace Prefix: | ptgx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of development milestone payable under the research and collaboration agreement. + References No definition available. + Details
Name: | ptgx_ResearchAndCollaborationAgreementDevelopmentMilestonePayable
Namespace Prefix: | ptgx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents upcoming potential development milestones payment. + References No definition available. + Details
Name: | ptgx_UpcomingPotentialDevelopmentMilestonesPayment
Namespace Prefix: | ptgx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_Ptg200PhaseAndSecondGenerationCompoundMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_ThreePhaseOneStudiesOfSecondGenerationCompoundsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_PhaseTwoClinicalTrialSecondIndicationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_PhaseThreeClinicalTrialForAnyIndicationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_ClinicalDataCollectionForPhase1ActivitiesPn232AndPn235Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ptgx_OriginalAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_SecondGenerationPhase2aAnd2bMilestonePaymentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_SecondGenerationPhase2StudiesMilestonePaymentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ptgx_UpfrontCashPaymentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ptgx_LicenseAndCollaborativeAgreementAmendedAndRestatedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_SecondGenerationOralInterleukinIl23ReceptorAntagonistDevelopmentCompoundMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_SecondGenerationPhase2aEvaluatingPtg200Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_FinancialServiceOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_PhaseOneStudiesOfSecondGenerationCompoundsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForAnyIndicationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_DosingOfThirdPatientInPhase3ClinicalTrialForSecondGenerationCompoundForSecondIndicationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |